A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of nivolumab + cisplatin-RT relative
to standard of care (SOC) cisplatin-RT alone, using the disease-free survival (DFS by
investigator imaging assessment) as primary endpoint )